These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 35487753)

  • 1. Achievement rate and predictive factors of the recommended therapeutical target in patients with axial spondyloarthritis who remain on biological therapy: a prospective cohort study in Spain.
    Benavent D; Franco-Gómez K; Plasencia-Rodriguez C; Novella-Navarro M; Bogas P; Nieto R; Monjo I; Nuño L; Villalba A; Peiteado D; Balsa A; Navarro-Compán V
    BMJ Open; 2022 Apr; 12(4):e057850. PubMed ID: 35487753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained low functional impairment in axial spondyloarthritis (axSpA): which are the primary outcomes that should be targeted to achieve this?
    Maksymowych WP; Inman RD; Bessette L; Rahman P; Rampakakis E; Asin-Milan O; Rachich M; Marrache AM; Lehman AJ
    Arthritis Res Ther; 2023 Apr; 25(1):70. PubMed ID: 37118833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Where we are in treat to target era? Predictive factors for remission and drug switching in patients with axial spondyloarthritis: a real-life evidence from BioStaR nationwide registry.
    Bodur H; Yurdakul FG; Ataman S; Cay HF; Gurer G; Capkin E; Sezer İ; Duruoz MT; Melikoglu MA; Rezvani A; Yagci I; Gogus F; Kamanli A; Akgul O; Cevik R
    Clin Rheumatol; 2022 Jul; 41(7):2053-2063. PubMed ID: 35353263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validity and reliability of the Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in patients with axial spondyloarthritis (axSpA) in Singapore.
    Kwan YH; Tan JJ; Phang JK; Fong W; Lim KK; Koh HL; Lui NL; Tan CS; Østbye T; Thumboo J; Leung YY
    Int J Rheum Dis; 2019 Dec; 22(12):2206-2212. PubMed ID: 31721427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis: going beyond BASDAI.
    Marona J; Sepriano A; Rodrigues-Manica S; Pimentel-Santos F; Mourão AF; Gouveia N; Branco JC; Santos H; Vieira-Sousa E; Vinagre F; Tavares-Costa J; Rovisco J; Bernardes M; Madeira N; Cruz-Machado R; Roque R; Silva JL; Marques ML; Ferreira RM; Ramiro S
    RMD Open; 2020 Jan; 6(1):. PubMed ID: 32144137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discriminant validity of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis: a cohort study.
    Kilic E; Kilic G; Akgul O; Ozgocmen S
    Rheumatol Int; 2015 Jun; 35(6):981-9. PubMed ID: 25366469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: a European routine-care observational study.
    Christiansen SN; Horskjær Rasmussen S; Ostergaard M; Pons M; Michelsen B; Pavelka K; Codreanu C; Ciurea A; Glintborg B; Santos MJ; Sari I; Rotar Z; Gudbjornsson B; Macfarlane GJ; Relas H; Iannone F; Laas K; Wallman JK; van de Sande M; Provan SA; Castrejon I; Zavada J; Mogosan C; Nissen MJ; Loft AG; Barcelos A; Erez Y; Pirkmajer KP; Grondal G; Jones GT; Hokkanen AM; Chimenti MS; Vorobjov S; Di Giuseppe D; Kvien TK; Otero-Varela L; van der Horst-Bruinsma I; Hetland ML; Ørnbjerg LM
    RMD Open; 2024 Jul; 10(3):. PubMed ID: 39053949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of remission in people with axial spondyloarthritis: A systematic literature review.
    Pinto AS; Farisogullari B; Machado PM
    Semin Arthritis Rheum; 2022 Oct; 56():152078. PubMed ID: 35944350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey.
    Lopalco G; Venerito V; Cantarini L; Emmi G; Salaffi F; Di Carlo M; Tafuri S; Gentileschi S; Di Scala G; Nivuori M; Cacciapaglia F; Galeazzi M; Lapadula G; Iannone F
    Clin Exp Rheumatol; 2019; 37(5):762-767. PubMed ID: 31025925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Procollagen I N-terminal peptide correlates with inflammation on sacroiliac joint magnetic resonance imaging in ankylosing spondylitis but not in non-radiographic axial spondyloarthritis: A cross-sectional study.
    Li X; Liang A; Chen Y; Lam NS; Long X; Xu X; Zhong S
    Mod Rheumatol; 2022 Jul; 32(4):770-775. PubMed ID: 34897520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of nociplastic and neuropathic pain components with the presence of residual symptoms in patients with axial spondyloarthritis receiving biological disease-modifying antirheumatic drugs.
    Al Mohamad F; Rios Rodriguez V; Haibel H; Protopopov M; Rademacher J; Sieper J; Torgutalp M; Käding H; Proft F; Poddubnyy D
    RMD Open; 2024 Feb; 10(1):. PubMed ID: 38360039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construct validity of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score (ASDAS) treatment target cut-offs in a BASDAI treat-to-target axial spondyloarthritis cohort: a cross-sectional study.
    Michielsens C; Bolhuis TE; van Gaalen FA; van den Hoogen F; Verhoef LM; den Broeder N; den Broeder AA
    Scand J Rheumatol; 2024 May; 53(3):180-187. PubMed ID: 37339375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Similar biologic drug response regardless of radiographic status in axial spondyloarthritis: data from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis registry.
    Michelena X; Zhao SS; Dubash S; Dean LE; Jones GT; Marzo-Ortega H
    Rheumatology (Oxford); 2021 Dec; 60(12):5795-5800. PubMed ID: 33502476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is there any gender-specific difference in the cut-off values of ankylosing spondylitis disease activity score in patients with axial spondyloarthritis?
    Kilic G; Kilic E; Ozgocmen S
    Int J Rheum Dis; 2017 Sep; 20(9):1201-1211. PubMed ID: 27309497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained low disease activity measured by ASDAS slow radiographic spinal progression in axial spondyloarthritis patients treated with TNF-inhibitors: data from REGISPONSERBIO.
    Llop M; Moreno M; Navarro-Compán V; Juanola X; de Miguel E; Almodóvar R; Quintana EC; Sanz JS; Beltrán E; Montesinos MDR; Calvet J; Berenguer-Llergo A; Gratacós J;
    Arthritis Res Ther; 2022 Jan; 24(1):30. PubMed ID: 35063018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration.
    Ørnbjerg LM; Linde L; Georgiadis S; Rasmussen SH; Lindström U; Askling J; Michelsen B; Giuseppe DD; Wallman JK; Pavelka K; Závada J; Nissen MJ; Jones GT; Relas H; Pirilä L; Tomšič M; Rotar Z; Geirsson AJ; Gudbjornsson B; Kristianslund EK; van Sder Horst-Bruinsma I; Loft AG; Laas K; Iannone F; Corrado A; Ciurea A; Santos MJ; Santos H; Codreanu C; Akkoc N; Gunduz OS; Glintborg B; Østergaard M; Hetland ML
    Semin Arthritis Rheum; 2022 Oct; 56():152081. PubMed ID: 35985172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of long-term clinical response in patients with non-radiographic axial spondyloarthritis receiving certolizumab pegol.
    Maksymowych WP; Kumke T; Auteri SE; Hoepken B; Bauer L; Rudwaleit M
    Arthritis Res Ther; 2021 Oct; 23(1):274. PubMed ID: 34715908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construct validity and responsiveness of the simplified version of Ankylosing Spondylitis Disease Activity Score (SASDAS) for the evaluation of disease activity in axial spondyloarthritis.
    Salaffi F; Ciapetti A; Carotti M; Gasparini S; Citera G; Gutierrez M
    Health Qual Life Outcomes; 2014 Aug; 12():129. PubMed ID: 25146299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort.
    Ramiro S; van der Heijde D; van Tubergen A; Stolwijk C; Dougados M; van den Bosch F; Landewé R
    Ann Rheum Dis; 2014 Aug; 73(8):1455-61. PubMed ID: 24812292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Ankylosing Spondylitis Disease Activity Score and Bath Ankylosing Spondylitis Disease Activity Index tools in assessment of axial spondyloarthritis activity.
    Wiąk-Walerowicz K; Wielosz E
    Reumatologia; 2024; 62(1):64-69. PubMed ID: 38558891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.